Identification

Name
Human Serum Albumin
Accession Number
DB00062  (BTD00059, BTD00089, BTD00101, BIOD00059, BIOD00089, BIOD00101, DB00096, DB00064)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Human serum albumin isolated from expired blood plasma. In the iodonated form ( I 131), it is used as a diagnostic radiopharmaceutical for intravenous imaging.

Protein structure
Db00062
Protein chemical formula
C2936H4624N786O889S41
Protein average weight
66472.2 Da
Sequences
> Human Serum Albumin Sequence
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL
Download FASTA Format
Synonyms
  • Albumin (human)
  • Albumin human
  • Albumin microspheres, human
  • Albumin, blood
  • Albumin, human
  • Human albumin
  • Microspheres of human albumin
  • Serum albumin
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-21Not applicableUs
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-21Not applicableUs
AlbukedSolution2.5 g/50mLIntravenousKedrion Biopharma, Inc.1976-08-26Not applicableUs
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-28Not applicableUs
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-28Not applicableUs
AlbukedSolution.05 g/mLIntravenousKedrion Biopharma, Inc.1976-08-26Not applicableUs
Albumin (Human)Solution250 g/1000mLIntravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2006-10-17Not applicableUs
Albumin (Human)Solution250 g/1000mLIntravenousOctapharma2006-10-17Not applicableUs
Albumin (Human)Solution50 g/1000mLIntravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2006-10-17Not applicableUs
Albumin (Human)Solution50 g/1000mLIntravenousOctapharma2006-10-17Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Albumin Human DiluentHuman Serum Albumin (.3 mg) + Sodium Chloride (9 mg)LiquidSubcutaneousOmega Laboratories Ltd1987-12-31Not applicableCanada
Sterile Diluent for Allergenic ExtractHuman Serum Albumin (.0003 mL/mL) + Phenol (.004 mL/mL)Injection, solutionIntradermal; SubcutaneousAntigen Laboratories, Inc.1974-03-23Not applicableUs
Categories
UNII
ZIF514RVZR
CAS number
9048-46-8

Pharmacology

Indication

For treatment of severe blood loss, hypervolemia, and hypoproteinemia.

Structured Indications
Pharmacodynamics

Serum albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.

Mechanism of action

Serum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It binds many other substances, such as unconjugated bilirubin, calcium ions, and other fat soluble hormones.

TargetActionsOrganism
UApolipoprotein ENot AvailableHuman
USerum amyloid A-1 proteinNot AvailableHuman
UProtein AMBPNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
No interactions found.
Food Interactions
Not Available

References

Synthesis Reference

Robert A. Tenold, "Preparing essentially monomeric normal human serum albumin." U.S. Patent USRE0362590, issued July, 1976. Rene Fickat, Simon Benita, Francis Puisieux, "Preparation of biodegradable microcapsules based on serum albumin." U.S. Patent US4666641, issued June, 1958.

USRE0362590
General References
  1. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S: Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003 Jul 7;3:6. Epub 2003 Jul 7. [PubMed:12846933]
External Links
UniProt
P02768
Genbank
M12523
PubChem Substance
46509098
ChEMBL
CHEMBL1201451
PharmGKB
PA164743293
RxList
RxList Drug Page
Wikipedia
Serum_albumin
ATC Codes
V08DA01 — Microspheres of human albumin
AHFS Codes
  • 16:00.00 — Blood Derivatives
  • 36:18.00 — Cardiac Function
  • 40:50.00* — Diluents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentHepatocellular,Carcinoma1
0WithdrawnDiagnosticRenal Cell Adenocarcinoma1
1CompletedDiagnosticAbdominal Trauma1
1CompletedDiagnosticNeoplasms, Abdominal / Pelvic Neoplasms1
1RecruitingTreatmentCardiomyopathy Due to Anthracyclines1
1TerminatedTreatmentPolyneuropathies1
1TerminatedTreatmentSubarachnoid Hemorrhage1
1, 2Active Not RecruitingDiagnosticVesico-Ureteral Reflux1
1, 2WithdrawnDiagnosticCoronary Artery Disease1
1, 2WithdrawnDiagnosticCrohn's Disease (CD)1
2Active Not RecruitingTreatmentIntermittent Claudication / Peripheral Artery Disease (PAD)1
2CompletedTreatmentAlpha 1-Antitrypsin Deficiency1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnginal Pain / Chronic Ischemic Heart Disease / Ischaemic Cardiomyopathy / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
2CompletedTreatmentMacular Degeneration1
2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentSymptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
2RecruitingDiagnosticRenal Cell Adenocarcinoma1
2RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2RecruitingTreatmentChronic Myocardial Ischemia1
2TerminatedDiagnosticCarotid Artery Diseases1
2TerminatedTreatmentCardiopulmonary Bypass / Systemic Inflammatory Response Syndrome (SIRS)1
2, 3Active Not RecruitingTreatmentAllergic Rhinitis (AR)2
2, 3Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentFibrinogen Deficiency in Complex Cardiac Surgery1
2, 3SuspendedTreatmentGraft Versus Host Disease (GVHD)1
2, 3TerminatedTreatmentHypovolaemia1
2, 3Unknown StatusNot AvailableSevere Head Injury1
3CompletedTreatmentLiver Cirrhosis1
3CompletedTreatmentMultifocal Motor Neuropathy (MMN)1
3CompletedTreatmentPolyradiculoneuropathy, Chronic Inflammatory Demyelinating1
3CompletedTreatmentSecondary Recurrent Miscarriage1
3RecruitingTreatmentPostoperative Kidney Injury1
3TerminatedTreatmentAcute Ischemic Stroke (AIS)1
3TerminatedTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentLiver Cirrhosis / Renal Failure / Sepsis1
3TerminatedTreatmentLung Injury, Acute (ALI) / Respiratory Distress Syndrome, Acute (ARDS)1
4CompletedNot AvailableEchocardiography1
4CompletedDiagnosticPulmonary Hypertension (PH)1
4CompletedPreventionHemorrhage1
4CompletedPreventionHepatic Encephalopathy1
4CompletedTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentHypoalbuminemia / Peptic Ulcer Bleeding1
4RecruitingDiagnosticNonvalvular Atrial Fibrillation1
4RecruitingDiagnosticTransplantation, Kidney1
4RecruitingTreatmentAlpha-1 Anti-trypsin Deficiency / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentHepatic Encephalopathy / Liver Cirrhosis1
4RecruitingTreatmentHypoalbuminemia1
4RecruitingTreatmentHypoalbuminemia / Shock / Systemic Inflammatory Response Syndrome (SIRS)1
4TerminatedTreatmentSpontaneous Bacterial Peritonitis (SBP)1
4TerminatedTreatmentMinor burns1
4Unknown StatusTreatmentHemorrhage; Complicating Delivery, Coagulation Defect1
4Unknown StatusTreatmentSecond or Third Degree Burns1
Not AvailableActive Not RecruitingTreatmentLiver Cirrhosis1
Not AvailableCompletedScreeningCancer, Breast1
Not AvailableNot Yet RecruitingNot AvailableHeart Transplantation1
Not AvailableRecruitingDiagnosticTransesophageal Echocardiography Contrast Agents1
Not AvailableRecruitingOtherEndothelial Dysfunction1
Not AvailableRecruitingTreatmentAortic Valve Disorder / Brain Injury / Coronary Heart Disease (CHD) / Renal Failure / Shock, Cardiogenic / Strokes1
Not AvailableRecruitingTreatmentAscites / Liver Cirrhosis1
Not AvailableRecruitingTreatmentHemodynamic Stability1
Not AvailableSuspendedDiagnosticAscites / Liver Cirrhosis1
Not AvailableTerminatedTreatmentSubarachnoid Hemorrhage1
Not AvailableUnknown StatusDiagnosticCoronary Artery Disease / Myocardial Perfusion Abnormalities1
Not AvailableWithdrawnDiagnosticCarotid Stenosis / Coronary Stenosis / Myocardial Reperfusion1
Not AvailableWithdrawnDiagnosticOvarian Hyperstimulation Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous.05 g/mL
SolutionIntravenous2.5 g/50mL
SolutionIntravenous5 g/20mL
SolutionIntravenous200 g/1000mL
SolutionIntravenous250 g/1000mL
SolutionIntravenous50 g/1000mL
LiquidSubcutaneous
SolutionIntravenous20 g/100mL
SolutionIntravenous25 g
SolutionIntravenous25 g/100mL
SuspensionIntravenous5 %
SolutionIntravenous5 %
SolutionIntravenous12.5 g/250mL
Injection, solutionIntravenous10 g/50mL
Injection, solutionIntravenous12.5 g/250mL
Injection, solutionIntravenous.05 g/mL
Injection, solutionIntravenous.25 g/mL
LiquidIntradermal; Subcutaneous0.03 %
SolutionIntravenous.25 g/mL
SolutionIntravenous10 g/50mL
SolutionIntravenous12.5 g/50mL
SolutionIntravenous20 %
Injection, solutionIntravenous12.5 g/50mL
LiquidIntravenous25 %
SolutionIntravenous25 %
SolutionIntravenous250 mg
SolutionIntravenous50 mg
Injection, solutionIntradermal; Subcutaneous
SolutionIntravenous0.03 %
Prices
Unit descriptionCostUnit
Buminate 25% iv solution2.22USD ml
Albumin 25% iv solution1.97USD ml
Albutein 25% vial1.32USD ml
Buminate 5% iv solution0.44USD ml
Albutein 5% iv solution0.43USD ml
Albumin (human) 5% iv solution0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5558094No1995-02-282012-02-28Us
US6723303No2001-04-202021-04-20Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)62 °CFlora, K. et al., Biophys J. 75:1084-1096 (1998)
hydrophobicity-0.395Not Available
isoelectric point5.67Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Very-low-density lipoprotein particle receptor binding
Specific Function
Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of ...
Gene Name
APOE
Uniprot ID
P02649
Uniprot Name
Apolipoprotein E
Molecular Weight
36153.83 Da
References
  1. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K: Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53. Epub 2006 Mar 22. [PubMed:16554356]
  2. Yamashita T, Kawashima S, Hirase T, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Inoue N, Hirata K, Yokoyama M: Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice. Am J Physiol Cell Physiol. 2007 Sep;293(3):C865-73. Epub 2007 Jun 6. [PubMed:17553935]
  3. Yuan ZY, Liu Y, Kishimoto C, Shioji K, Yokode M, Liu ZQ: [The Fc region of immunoglobulin suppresses atherosclerosis in apolipoprotein E knockout mice]. Zhonghua Yi Xue Za Zhi. 2003 Mar 25;83(6):489-93. [PubMed:12887764]
  4. Mojzisova H, Bonneau S, Vever-Bizet C, Brault D: The pH-dependent distribution of the photosensitizer chlorin e6 among plasma proteins and membranes: a physico-chemical approach. Biochim Biophys Acta. 2007 Feb;1768(2):366-74. Epub 2006 Oct 25. [PubMed:17141733]
  5. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M: Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H899-906. [PubMed:12860569]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Heparin binding
Specific Function
Major acute phase protein.
Gene Name
SAA1
Uniprot ID
P0DJI8
Uniprot Name
Serum amyloid A-1 protein
Molecular Weight
13531.885 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Small molecule binding
Specific Function
Inter-alpha-trypsin inhibitor inhibits trypsin, plasmin, and lysosomal granulocytic elastase. Inhibits calcium oxalate crystallization.Trypstatin is a trypsin inhibitor.
Gene Name
AMBP
Uniprot ID
P02760
Uniprot Name
Protein AMBP
Molecular Weight
38999.215 Da
References
  1. Sala A, Campagnoli M, Perani E, Romano A, Labo S, Monzani E, Minchiotti L, Galliano M: Human alpha-1-microglobulin is covalently bound to kynurenine-derived chromophores. J Biol Chem. 2004 Dec 3;279(49):51033-41. Epub 2004 Sep 27. [PubMed:15452109]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou Q, Matsumoto S, Ding LR, Fischer NE, Inaba T: The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci. 2004 Sep 17;75(18):2145-55. [PubMed:15325841]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peroxidase activity
Specific Function
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
Gene Name
MPO
Uniprot ID
P05164
Uniprot Name
Myeloperoxidase
Molecular Weight
83867.71 Da
References
  1. Salavej P, Spalteholz H, Arnhold J: Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic Biol Med. 2006 Feb 1;40(3):516-25. Epub 2005 Nov 9. [PubMed:16443167]
  2. Senthilmohan R, Kettle AJ: Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch Biochem Biophys. 2006 Jan 15;445(2):235-44. Epub 2005 Aug 3. [PubMed:16125131]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Rowland A, Knights KM, Mackenzie PI, Miners JO: The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62. doi: 10.1124/dmd.108.021105. Epub 2008 Mar 24. [PubMed:18362158]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33